ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses.
Onuigbo
Macaulay A C
MA
D047228:Angiotensin II Type 1 Receptor Blockers / Q000009:adverse effects / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002752:Chlorthalidone / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D048909:Diabetes Complications / Q000517:prevention & control; D004359:Drug Therapy, Combination; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D007676:Kidney Failure, Chronic / Q000517:prevention & control; D015201:Meta-Analysis as Topic; D009203:Myocardial Infarction / Q000517:prevention & control*; D051437:Renal Insufficiency / Q000139:chemically induced; D049993:Sodium Chloride Symporter Inhibitors / Q000627:therapeutic use
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D000960:Hypolipidemic Agents; D049993:Sodium Chloride Symporter Inhibitors; D002752:Chlorthalidone